Tesaro earns CHMP thumbs-up for Zejula as three-way PARP race heats up
admin 15th September 2017 Uncategorised 0Just last month, Tesaro seemed to be in danger of losing its lead in the market for PARP inhibitors to treat ovarian cancer. Now, the company is in strong position to win another regulatory victory for its drug Zejula that could boost its standing in the market, this one from Europe.
More: Tesaro earns CHMP thumbs-up for Zejula as three-way PARP race heats up
Source: fierce